Anavex Life Sciences (US.AVXL)
资本配置审计 · 期间： 2010 – 2026
核心指标
US.AVXL · 同比： 2026 H1 vs 2025 H1
| 指标 | 数值 | 同比 |
|---|---|---|
| FCF Conversion | - | → |
| ROE | -9.1% | ↑ |
| Cash Conversion | - | → |
| D/E Ratio | 0.00 | ↓ |
| Gross Margin | - | → |
US.AVXL (Anavex Life Sciences) | YoY: 2026 H1 vs 2025 H1 Metric Value YoY --------------------------- FCF Conversion - → ROE -9.1% ↑ Cash Conversion - → D/E Ratio 0.00 ↓ Gross Margin - →
核心指标
US.AVXL (Anavex Life Sciences) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY---------------------------FCF Conversion - →ROE -9.1% ↑Cash Conversion - →D/E Ratio 0.00 ↓Gross Margin - →免费公司
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies